Scholar Rock Holding Corporation (SRRK)

NASDAQ: SRRK · IEX Real-Time Price · USD
7.81
-0.80 (-9.29%)
At close: Mar 24, 2023, 4:00 PM
8.02
+0.21 (2.69%)
After-hours: Mar 24, 2023, 4:06 PM EDT
-9.29%
Market Cap 406.00M
Revenue (ttm) 33.19M
Net Income (ttm) -134.50M
Shares Out 51.99M
EPS (ttm) -2.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 215,223
Open 8.46
Previous Close 8.61
Day's Range 7.65 - 8.49
52-Week Range 4.33 - 15.43
Beta 0.78
Analysts Buy
Price Target 23.02 (+194.75%)
Earnings Date Mar 7, 2023

About SRRK

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-P... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 24, 2018
Employees 145
Stock Exchange NASDAQ
Ticker Symbol SRRK
Full Company Profile

Financial Performance

In 2022, SRRK's revenue was $33.19 million, an increase of 76.41% compared to the previous year's $18.82 million. Losses were -$134.50 million, 2.05% more than in 2021.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for SRRK stock is "Buy." The 12-month stock price forecast is $23.02, which is an increase of 194.75% from the latest price.

Price Target
$23.02
(194.75% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a f...

2 weeks ago - Business Wire

Scholar Rock to Present 24-Month Data from the Phase 2 TOPAZ trial at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a ...

3 weeks ago - Business Wire

Scholar Rock to Present at the Cowen 43rd Annual Health Care Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a f...

3 weeks ago - Business Wire

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a...

1 month ago - Business Wire

Scholar Rock Provides Corporate Update and Highlights Priorities for 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a...

2 months ago - Business Wire

Scholar Rock to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a...

2 months ago - Business Wire

Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a...

4 months ago - Business Wire

Scholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a...

4 months ago - Business Wire

Scholar Rock Appoints Jing L. Marantz, M.D.

CAMBRIDGE, Mass.

4 months ago - Business Wire

Scholar Rock to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass.

4 months ago - Business Wire

Scholar Rock to Present Data from the Phase 1 DRAGON trial at the SITC 37th Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock to Present Data from DRAGON, a Phase 1 proof-of-concept study of SRK-181 in patients with advanced solid tumors, at SITC Annual Meeting.

6 months ago - Business Wire

Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at Two International Conferences: World Muscle Society Congress and International Scientific Congress on Spinal Muscular Atrophy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at WMS Congress and International Scientific Congress on Spinal Muscular Atrophy.

6 months ago - Business Wire

Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer

6 months ago - Business Wire

Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit

6 months ago - Business Wire

Scholar Rock Reports Second Quarter 2022 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a f...

8 months ago - Business Wire

Scholar Rock Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced that Dr. Srinivas Akkaraju has been appointed to Scholar Rock's Board of Directors as an independent director.

8 months ago - Business Wire

Scholar Rock to Participate in the 2022 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a ...

8 months ago - Business Wire

Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGFβ1 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced the company will present new data at the 2022 FASEB Science Research Conference (SRC), taking place between July 17–21, 2022.

9 months ago - Business Wire

Does Scholar Rock Holding Corporation (SRRK) Have the Potential to Rally 246% as Wall Street Analysts Expect?

The consensus price target hints at a 246.1% upside potential for Scholar Rock Holding Corporation (SRRK). While empirical research shows that this sought-after metric is hardly effective, an upward t...

9 months ago - Zacks Investment Research

Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced an e-poster presentation on the ongoing SAPPHIRE Phase 3 clinical trial in spinal muscular atrophy (SMA) at ICNMD 2022.

9 months ago - Business Wire

How Much Upside is Left in Scholar Rock Holding Corporation (SRRK)? Wall Street Analysts Think 394%

The consensus price target hints at a 394.4% upside potential for Scholar Rock Holding Corporation (SRRK). While empirical research shows that this sought-after metric is hardly effective, an upward t...

9 months ago - Zacks Investment Research

Why Scholar Rock Shares Are Trading Higher Today

Scholar Rock Holding Corp (NASDAQ: SRRK) announced new data from the Phase 2 TOPAZ trial extension period evaluating apitegromab in non-ambulatory patients with Types 2 and 3 Spinal Muscular Atrophy (...

10 months ago - Benzinga